Explore how GLP-1 agonists, originally for diabetes, could transform addiction treatment by reducing cravings.

Novo Nordisk - which manufactures Wegovy, Ozempic and Saxenda - misreported, under-reported or did not disclose funding it ...

Josh Gad says he's taking 'life-changing' GLP-1 medication for weight loss but admits that it can't replace having a healthy ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Patients with metabolic dysfunction-associated steotohepatitis (MASH) who are already taking a glucagon-like peptide-1 ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

The company behind popular weight-loss drugs failed to disclose millions of pounds it paid to healthcare groups and patient ...

Health experts have issued a new warning about the online sale of weight-loss jabs.The focus of these fresh updates were the ...

The pharmacy association said it was worried some patients were accessing the drugs inappropriately amid a surge in demand.View on euronews ...

The National Pharmacy Association (NPA) has written to regulators calling for tougher rules to be introduced around sale of weight loss jabs online.

An observational analysis has found that the drugs may lower the risk of substance abuse and cognitive issues. But the findings need clinical testing.

Novo Nordisk has reported topline outcomes from a Phase Ib/IIa trial of amycretin designed for treating obese or overweight ...